Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

07/23/2012 | 05:04am US/Eastern

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
React to this article
Latest news
Date Title
12:13p NETFLIX : Completing the Netflix Cloud Migration
12:13p NGFA NATIONAL GRAIN AND FEED ASSOCIATION : announces staff promotions
12:13p ICSID CENTRE FOR SETTLEMENT OF INV : Introduction to ICSID Process for Law Students, Washington D.C.
12:13p SUPERGROUP : Founder To Offload 4.9% Stake (DIRECTOR DEALINGS SUMMARY)
12:13pDJLONDON MARKETS : FTSE 100 Knocked To Lowest Since 2012 As Financials, Resources Slump
12:13p The "Timeless" Red Baron® Pizza Turns 40
12:12p BRIEF : Yarmouth-based mapmaker DeLorme sold to Garmin
12:12p Siemens and Utilidata Announce Grid Reliability & Optimization Solution
12:12p Caltrain Uses Acrow Bridge Steel Structures During Replacement of Pedestrian Walkways in San Francisco
12:10p NATUREX : Number of shares and voting rights as at 31 January 2016
Latest news
Advertisement
Hot News 
IMPERIAL TOBACCO : Trading Statement for the three months ended 31st December 2015
UBISENSE : and Van Meter form Strategic Partnership in North America
Blue Nile Announces Fourth Quarter and Full Year 2015 Financial Results; First-Ever Special Dividend
FLOWERS FOODS : misses Street 4Q forecasts
RIVER AND MERCANTILE : & Mercantile Group Assets Boosted By Net Inflows
Most Read News
01:32a PERNOD RICARD :  Organizational Changes
04:36a KONINKLIJKE FRIESLANDCAMPINA NV : FrieslandCampina and Glycosyn partner for new infant nutrition ingredients
02/10 AUSTRALIAN GREENS : Estimates: Melbourne airport third runway
08:32a Outdoor Industry Veteran Maile Buker Joins Chimani's Board of Directors
12:03a Gold demand resilient in 2015 as central banks and consumers spur strong H2 recovery
Most recommended articles
12:05p Global shares plunge on global growth, bank fears; U.S. yields tumble
12:02p Shares plunge on global growth, bank fears; U.S. yields tumble
12:02pDJYellen Reiterates Concerns About Risks to Economy in Senate Testimony -- Update
11:54aDJU.S. Cattle Futures Slide on Pressure in Outside Markets
11:53a Yellen says no clear timeline on when oil, dollar will stabilize